DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study to Evaluate Diphenhydramine in Children and Adolescents

Information source: Johnson & Johnson Consumer and Personal Products Worldwide
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Allergic Rhinitis

Intervention: diphenhydramine HCl (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Johnson & Johnson Consumer and Personal Products Worldwide

Official(s) and/or principal investigator(s):
Cathy M Gelotte, PhD, Study Director, Affiliation: McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.


To characterize the pharmacokinetics of diphenhydramine in two pediatric populations: children, ages 2 to < 12 years, and adolescents, ages 12 to < 18 years.

Clinical Details

Official title: An Open-Label, Single-Dose Study Evaluating the Pharmacokinetics of Diphenhydramine in Children and Adolescents

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome: Pharmacokinetic parameters

Secondary outcome: Safety Assessments will consist of monitoring vital signs and all non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs), their frequency, severity, seriousness, and relationship to the investigational product.

Detailed description: This study has an open-label, single-dose classical pharmacokinetic design with no comparator treatment or group. Twenty-four (24) children, ages 2 to < 12 years, and 12 adolescents, ages 12 to < 18 years, with symptoms due to hay fever or other upper respiratory allergies will complete the study. To ensure that younger children are represented, at least 35% (8) of the children enrolled will range from 2 to < 6 years of age.


Minimum age: 2 Years. Maximum age: 17 Years. Gender(s): Both.


Inclusion Criteria:

- Male and female children and adolescents, ages 2 to < 18 years, with a minimum weight

of 24 pounds will be eligible to participate. In addition, each subject will be > 5th percentile and < 95th percentile for weight based on age and gender.

- Subjects will have a body mass index (BMI) > 5th percentile and less than or equal to

90th percentile for age and gender.

- Subjects who have a history of allergic rhinitis and who are experiencing symptoms

due to hay fever or other upper respiratory allergies will be included.

- Subjects who do not use concurrent medications, except for low-dose inhaled

glucocorticosteroids for allergic rhinitis or mild concurrent asthma, if dose is stabilized before entry in the study (ie, dose is not changed for 1 month prior to entry or during the study), and inhaled short-acting beta-2 adrenergic agonists for concomitant asthma, as needed; Exclusion Criteria:

- Evidence or history of clinically significant hematological, renal, endocrine,

pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurologic disease.

- Findings from the medical history or physical examination with vital sign

measurements that are not within the range of clinical acceptability.

- Have a known sensitivity or allergy to diphenhydramine or EMLA cream.

- Have a known sensitivity or allergy to red dye.

- Have asthma symptoms at the time of study entry or requiring medications other than

allowed in Inclusion Criterion 4;

- Took any prescription (other than allowed in Inclusion Criterion 4) or

nonprescription medication, within seven days or five half-lives (whichever is longer) before the study's start date.

- Took any herbal supplements or drank grapefruit juice with 28 days of the study's

start date.

- Participated in, or completed, another clinical trial within seven weeks before the

study's start date.

- Have a history of drug, alcohol, and tobacco use (older children and adolescents)

- Have a history of hepatitis B, a previous positive test for hepatitis B surface

antigen, or a previous positive hepatitis C antibody.

- Have a history of HIV infection or previous demonstration of HIV antibodies.

- Pregnant or nursing females; females of childbearing potential who are unwilling or

unable to use an acceptable method of contraception from at least three months prior to the first dose of study medication until completion of follow-up procedures.

Locations and Contacts

Arkansas Medical Research Testing Center, Little Rock, Arkansas 72202, United States
Additional Information

Starting date: September 2008
Last updated: October 4, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017